Assessment of an Automatic Closed-loop Insulin Delivery System

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Official Title

Assessment of an Automatic Closed-loop Insulin Delivery System

Eligibility Criteria

Ages Eligible for Study: 14 Years to 40 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. 1. Clinical diagnosis of type 1 diabetes - The diagnosis of type 1 diabetes is based on the investigator's judgment - C peptide levels and antibody determinations are not required 2. Daily insulin therapy for ≥ 12 months 3. Insulin pump therapy for ≥ 3 months 4. Age 14.0 - 40.0 years 5. Subject comprehends written English 6. Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD 7. Female subjects past menarche must have a negative urine pregnancy test 8. Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age 9. For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.
Exclusion Criteria:
  1. 1. Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol 2. Diabetic ketoacidosis in the past month 3. Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months 4. Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis 5. Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease 6. Subject has a history of liver or kidney disease (other than microalbuminuria) 7. Subject has active Graves' disease 8. Subjects with inadequately treated thyroid disease or celiac disease 9. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol 10. Subject has a history of diagnosed medical eating disorder 11. Subject has a history of known illicit drug abuse 12. Subject has a history of known prescription drug abuse 13. Subject has a history of current alcohol abuse 14. Subject has a history of visual impairment which would not allow subject to participate 15. Subject has an active skin condition that would affect sensor placement 16. Subject has adhesive allergies 17. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine) 18. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable) 19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study 20. Subject is currently on beta blocker medication 21. Subject is currently participating in another investigational study (drug or device) 22. Subject is deemed by the investigator to be unwilling or unable to follow the protocol 23. Presence of a febrile illness within 24 hours of enrollment


Bruce Buckingham
Bruce Buckingham
Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus